CC-90009
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $470,083 | 11 | 5 |
| 2018 | $376,903 | 7 | 0 |
| 2017 | $322,457 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 24 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1, Open-label, Dose Finding Study of CC-90009, a Novel Cereblon E3 Ligase Modulating Drug, in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes (CC-90009-AML-001) | Celgene Corporation | $370,154 | 5 |
| CC-90009-AML-001 | Celgene Corporation | $322,457 | 0 |
| CC-90009-AML-001 - A Phase 1, Open-label, Dose Finding Study of CC-90009, a Novel Cereblon E3 Ligase Modulating Drug, in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk | Celgene Corporation | $310,236 | 0 |
| An Exploratory Phase 1b Open-label Multi-arm Trial to Evaluate the Safety and Efficacy of CC 90009 in Combination with Anti-Leukemia Agents in Subjects with Acute Myeloid Leukemia (CC-90009-AML-004) | Celgene Corporation | $99,929 | 0 |
| CC-90009 Non-Specific SD - Development of Humanized Ossicle Xenotransplant Model | Celgene Corporation | $66,667 | 0 |
Top Doctors Receiving Payments for CC-90009
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Hackensack, NJ | $1.2M | 19 |
| , MD | Hematology & Oncology | Chicago, IL | $2,079 | 1 |
| , MD | Hematology & Oncology | Saint Louis, MO | $2,079 | 1 |
| , M.D | Hematology | Washington, DC | $2,079 | 1 |
| , M.D.,PH.D | Hematology & Oncology | Boston, MA | $2,079 | 1 |
| Amer Zeidan | Hematology & Oncology | New Haven, CT | $2,079 | 1 |
Manufacturing Companies
- Celgene Corporation $1.2M
Product Information
- Type Drug
- Total Payments $1.2M
- Total Doctors 5
- Transactions 24
About CC-90009
CC-90009 is a drug associated with $1.2M in payments to 5 healthcare providers, recorded across 24 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2017 to 2019. In 2019, $470,083 was paid across 11 transactions to 5 doctors.
The most common payment nature for CC-90009 is "Unspecified" ($1.2M, 100.0% of total).
CC-90009 is associated with 5 research studies, including "A Phase 1, Open-label, Dose Finding Study of CC-90009, a Novel Cereblon E3 Ligase Modulating Drug, in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes (CC-90009-AML-001)" ($370,154).